SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-16-039372
Filing Date
2016-10-03
Accepted
2016-10-03 16:05:51
Documents
3
Period of Report
2016-09-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20160930_8k.htm 8-K 29285
2 EXHIBIT 4.1 ex4-1.htm EX-4.1 32614
3 EXHIBIT 10.1 ex10-1.htm EX-10.1 54664
  Complete submission text file 0001437749-16-039372.txt   118194
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24477 | Film No.: 161915822
SIC: 2834 Pharmaceutical Preparations